It is well recognized that blood lipoprotein A [Lp(a)] levels constitute an important risk factor for atherosclerotic vascular disease. In some populations, mainly Caucasian, Lp(a) levels and coronary heart disease (CHD) risk are determined by the pattern of apolipoprotein a [apo(a)] polymorphism. It is currently unclear if these observations apply to other populations and ethnic groups. The aim of the current study is to determine to what extent known apo(a) polymorphisms associate with development of CHD in a Kuwaiti Arab population.
Many prospective and case±control studies have identi®ed elevated lipoprotein a [Lp(a)] levels as an independent risk factor for premature atherosclerotic disease. 1±4 There are, however, a few negative studies 5, 6 in which the link between serum Lp(a) levels and predisposition to atherosclerotic vascular disease is not so clear cut. Why some of the studies were negativeremains unclear. Marcovina et al. suggested that it may be due to isoform size bias, with misrepresentation of the true Lp(a) concentration. 7 In other studies, there may have been a gender bias in that the association is present in men and not in women. 8 Another possible cause is a true genetic difference between study populations. These genetic factors differ between races and ethnic groups, 4 and genetic heterogeneity between populations may have contributed to the inconsistencies described, particularly in non-Caucasian populations in which there are fewer reported studies.
We have previously reported on the levels and distribution of serum Lp(a), the pattern of apolipoprotein a [apo(a)] polymorphism and the association of a variety of biochemical and anthropometric variables with serum Lp(a) levels in a Kuwaiti Arab population. 9, 10 The aim of the current study was to determine to what extent known apo(a) polymorphisms associate with the development of coronary heart disease (CHD) in this population, which is currently experiencing increasing CHD rates.
SUBJECTS AND METHODS

Subjects
Two groups of Kuwaiti subjects were recruited from the general Kuwaiti adult population. Kuwait is a city-state in the north-eastern tip of the Arabian Gulf region, with a relatively small and homogeneous Kuwaiti adult population of about 300 000, distributed in ®ve governorates. The volunteers were recruited from all the representative areas of Kuwait by direct contact, telephone and through female ®eld staff. Other details of our recruitment procedure have been described previously. 9 The task was simpli®ed by the relatively small geographical area of the state of Kuwait, and also by the fact that our teaching hospital and medical school is the only one in the country, providing specialist country-wide service. The two groups of Kuwaiti subjects invited to participate in the study were as follows. The ®rst group, the healthy group, comprised 140 (64 male, 76 female) healthy subjects recruited randomly from the general Kuwaiti adult population. The second group, patients with CHD, comprised 140 (102 male, 38 female) stable patients who had been admitted more than 6 months previously for myocardial infarction (with classic clinical features, electrocardiograph abnormalities and plasma biochemical changes) and/or for coronary artery bypass grafting (CABG) for multiple coronary artery disease con®rmed on angiography. These patients were ambulant, not acutely ill and on regular cardiology and lipid clinic follow-up care. Of these, 96 were diabetic (type 2, noninsulin-dependent) with good control using small daily doses of oral sulphonylureas. Overrepresentation of diabetic patients in this group is a re¯ection of our unpublished observations and anecdotal reports of a diabetic prevalence rate of about 50% in the Kuwaiti population presenting with acute myocardial infarction.
The recruited subjects were aged 17±60 and ambulant, with no other acute systemic illness. The studies were approved by the local Research Ethics Committee.
Laboratory analysis
Venous blood samples were collected from each of the subjects in the morning (at 08´00±09´00 h), after a 12±14-h overnight fast, and analysed for serum lipids [total cholesterol (TC), triglycerides (TG)], uric acid, Lp(a), insulin and glucose. Serum was extracted after separation of the blood samples in a refrigerated centrifuge (1800 g, 25 min) within 1 h of specimen collection. Samples not analysed immediately were stored frozen at 3 80 Ê C until analysis (always within 3 months of collection). The measurements of TC, TG, uric acid and glucose were performed in the clinical biochemistry laboratory of the Faculty of Medicine, Department of Pathology building, using an Autoanalyser (Hitachi 911, Boehringer-Mannheim, Mannheim, Germany) with dedicated reagents also obtained from Boehringer-Mannheim. Lp(a) was determined by enzyme-linked immunosorbent assay (ELISA) using kits (TintElize Lp(a)) and controls supplied by Biopool, Umea, Sweden. Our intra-and inter-assay coef®cients of variation (CVs) for this method were 2´0% and 2´3%, respectively. Serum insulin levels were measured using ELISA kits (DAKO Diagnostics, Cambridgeshire, UK), which produces insulin results not in¯uenced by hyperlipidaemia and devoid of appreciable cross-reactivity with pro-insulin and pro-insulin split products. Intra-and inter-assay CVs obtained using this method were 7´5% and 8´8%, respectively.
Apo(a) isoforms were separated using highresolution sodium dodecyl sulphate/agarose gel electrophoresis, as previously reported. 11, 12 The modi®cations made to these original protocols have been described earlier. 9, 13 After electrophoresis, the separated proteins were transferred to a nitrocellulose membrane and identi®ed by immunoblotting. Immunodetection was performed with a Lp(a) phenotyping kit (IMMU-NO AG, Vienna, Austria), which contained anti-human sheep Lp(a), anti-sheep IgG (Fc)± alkaline phosphatase conjugate (rabbit), Lp(a) specimen buffer, phosphatase developer (5-bromo4-chloro3-indoxylphosphate, nitroblue tetrazolium) and human standard for Lp(a) isoforms. The latter contained ®ve known Lp(a) isoforms ± F, S1, S2, S3 and S4 ± according to Utermann's nomenclature, 14 with respective kringle-IV repeats of 14, 19, 23, 27 and 35, respectively, and was always included in duplicate in each run. A representative pattern of apo(a) phenotypes is indicated in Fig. 1 .
Data analysis
Results are expressed as mean 6 SD (standard deviation), median and range appropriate to the distribution of the data. The generated data between the healthy group and the CHD group were compared for quantitative parameters (e.g. age, glucose, uric acid, TC, TG, Lp(a) and insulin) using Mann±Whitney U tests, and for qualitative parameters (frequencies of apo(a) isoforms) using w 2 tests. These statistical tests were performed using the Statistical Package for the Social Sciences (SPSS). 15 The level of statistical signi®cance was P< 0´05. Table 1 shows the demographic, anthropometric and biochemical characteristics of the healthy control group and the CHD group. There were no differences in any of the parameters between males and females in either group, so further gender-based data analysis was not done.
RESULTS
The healthy subjects, none of whom was diabetic, were slightly younger than those with CHD. Levels of blood lipids (TC and TG) were greater in those with CHD, as were those for urate, Lp(a) and insulin. The levels for glucose indicated the expected differences between the non-diabetic and diabetic subjects with CHD. Almost similar numbers of healthy subjects (n=140) and those with CHD (n=128) had apo(a) phenotyping. Twelve of the originally recruited diabetic subjects did not have apo(a) phenotyping for two reasons: insuf®cient sample (n=7), and uninterpretable isoform pattern (n=5). As indicated in Table 2 , approximately equal proportions of either group (healthy versus CHD) had single-banded (homozygous, , 70%), double-banded (heterozygous, , 23%) and no-band (null, , 7%) phenotype (P not signi®cant). The`null' isoform was seen in 6´4% of the healthy group and 8´6% of the CHD group (P not signi®cant). Similarly, the distribution of the ®ve identi®ed isoforms ± F, S1, S2, S3 and S4 ± was essentially similar for both groups of subjects (P not signi®cant). For instance, the two most commonly identi®ed isoforms for either group were S3 and S4 (respectively 26% and 21% for the healthy group, and 36% and 16% for the CHD group). Both these isoforms contributed close to 50% of the isoforms identi®ed. Furthermore, for those subjects with heterozygous bands, those with either S3 or S4 isoforms, or both, constituted the clear majority. Indeed, if the total number of subjects (heterozygotes and homozygotes) with the respective isoforms were calculated, the following results were obtained: healthy group ± total S1: 15%; S2: 19%; S3: 44%; and S4: 37%; CHD group ± total S1: 12%; S2: 19%; S3: 58%; and S4: 25%. These results again indicate a close similarity in isoform distribution between the healthy subjects and those with CHD.
It is customary to divide the isoforms on the basis of their electrophoretic migration speed into fast-moving (F, S1 and S2) and slowmoving (S3 and S4). 4, 9, 13, 16 This speed, in turn, is dependent on their molecular size and the respective numbers of kringle-IV repeats. Healthy subjects with homozygous band patterns had 33% fast-moving and 67% slow-moving isoforms; in those with CHD, a similar pattern was seen, with 24% fast-moving and 76% slowmoving isoforms. When subjects who were heterozygotes containing at least one of the fastor the slow-moving isoforms were included, the healthy control subjects had 36% fast-moving and 81% slow-moving isoforms; in those with CHD, the pattern was similar again, with 30% having fast-moving and 83% slow-moving isoforms.
When the speci®c isoforms were related to their median Lp(a) concentrations, there was no consistent pattern identi®able for either group of subjects (see Table 2 ). While those with the`null' phenotype appeared to have the smallest Lp(a) concentrations for either group, the CHD`null' values were higher than the healthy`null' values (P=0´06), although the respective subject numbers were relatively small. Otherwise there was no signi®cant trend of increasing Lp(a) values with more rapid isoform electrophoretic migration speed (see Table 2 ).
DISCUSSION
The genetic in¯uence on circulating Lp(a) concentrations 17,18 is exerted mainly via changes in apo(a) polymorphisms between individuals and races. Apo(a) is very highly polymorphic owing to varying numbers of its kringle-IV type II domains; to date, at least 34 phenotypes have been described 11 ranging from 20 to 50 kringle-IV domains. Many published reports, mainly in Caucasian populations, suggest that the variable number of identical tandemly arranged transcribed kringle-IV type 3 repeats correlates inversely with the plasma Lp(a) concentration and may be the major determinant of the circulating serum Lp(a) level. 14, 16, 19, 20 Furthermore, it was hypothesized that this polymorphic pattern of serum Lp(a) is a useful predictor of CHD risk whether in the individual or in the population.
In different populations, it has been estimated that between 41 and 90% of the serum concentration is determined by the apo(a) polymorphism. 4, 11, 21, 22 This percentage contribution of apo(a) isoform distribution to blood Lp(a) levels, however, varies between populations and ethnic groups; in Sudanese blacks, for instance, apo(a) polymorphism contributes only about 19% to circulating Lp(a) levels. 4 Indeed, Scholz et al. 23 recently reported that the genetic control of Lp(a) levels is different between Africans and Caucasians and possibly between other ethnic or racial groups. There is the possibility, therefore, that the relationship between apo(a) isoform distribution and risk for development of CHD differs between racial groups.
In further exploration of this hypothesis, the results from this study suggest several things. First, Lp(a) levels were greater in individuals with CHD. This is in keeping with observations elsewhere that Lp(a) is an important CHD risk factor. 1±4 Additionally, individuals with CHD had relatively increased insulin, TG and urate levels ± these are components of the so-called Syndrome X' which confers additional predisposition to CHD. 24±26 Second, there is a relatively high frequency of the single-banded phenotype in the Arab Kuwaiti population studied, whether healthy (70%) or with CHD (68%). Indeed, the proportions of individuals with single-banded phenotypes were similar for both subject groups.
Third, there is no simple relationship between the apo(a) isoform distribution and the blood Lp(a) concentration in either subject group studied. Within both subject groups, differences in Lp(a) levels between the different isoforms were essentially trivial and failed to achieve statistical signi®cance. This agrees with our earlier observations, albeit in a group of healthy, relatively younger Kuwaiti Arab subjects. 9 Fourth, the apo(a) isoform distribution was similar in the healthy control population and in patients with CHD. Indeed, the relative frequencies of the respective isoforms ± low molecular weight, fast moving (F, S1 and S2) and the higher molecular weight, slowly migrating (S3 and S4) ± appeared similar between patients with CHD and healthy controls. No particular isoform was more frequently represented in the CHD group.
The results described here con¯ict with other reported observations in disparate populations in Austria 14 , Israel, 19 Germany, Wales, Singapore (resident Chinese and Indians), 16, 20 where the apo(a) isoforms associated with the high Lp(a) levels (F, S1 and S2) were signi®cantly more frequent in patients with CHD than in healthy controls. However, Sandholzer et al. 27 have also shown, in studies in seven ethnic groups, including Malays and black Sudanese, that differences in apo(a) allele frequencies do not explain the differences in Lp(a) levels among populations. They also demonstrated that in many populations, Lp(a) levels are mainly determined by factors that are different from the apo(a) polymorphism. The results from this study extend those latter observations in suggesting that the effect of blood Lp(a) levels in increasing risk for CHD is not mediated solely by apo(a) gene variability in all populations. Furthermore, our results reinforce the contention that Lp(a) levels and pattern of apo(a) polymorphism and its relationship with CHD risk differs between population groups. 9,27±29 Patients with CHD were older and expressed a worse lipid and lipoprotein pro®le than healthy control subjects. Furthermore, about 70% of those with CHD were diabetic. It is unlikely, however, that these differences could have accounted for the pattern of our observations for the following reasons: ®rst, apo(a) polymorphism is genetically determined and thus unlikely to be in¯uenced by temporal factors. Second, it has been reported that Lp(a) levels are in¯uenced by only a few metabolic and anthropometric factors, particularly body mass and LDL levels. 9,10 Lp(a) levels do not differ signi®cantly between diabetic and non-diabetic subjects and do not correlate signi®cantly with circulating insulin levels. 9, 31 Age is also not a signi®cant determinant of Lp(a) levels in our population. 9,10
CONCLUSION
These results suggest that the frequency and pattern of distribution of apo(a) phenotypes did not differ signi®cantly between healthy control Kuwaiti Arab subjects and those with CHD. It is thus unlikely that an individual's apo(a) phenotype can predict both his/her serum Lp(a) level and his/her risk for CHD, irrespective of race and/or ethnic grouping.
